Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
1. A method for reducing airway inflammation in a subject which develops airway inflammation in response to exposure to an allergen, the method comprising the step of infecting the subject with a live Bordetella pertussis strain which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT), wherein the step of infecting the subject results in reduction of airway inflammation in said subject.
2. The method of claim 1 , wherein the subject has been diagnosed with asthma.
3. The method of claim 1 , wherein the subject has been diagnosed with interstitial lung disease.
4. The method of claim 1 , wherein the subject has been diagnosed with hay fever.